Alli Sales Top 2 Million Starter Packs, Drive GSK’s OTC Sales
This article was originally published in The Tan Sheet
Executive Summary
GlaxoSmithKline's over-the-counter product sales posted a 24 percent increase to $854.6 million for the third quarter, driven in by U.S. sales of its alli weight loss drug, the firm said in an Oct. 24 earnings call